Summary
The product Sample 2, manufactured by NeoAnabolics, underwent independent testing to verify its authenticity and potency. The sample was submitted by NeoAnabolics@proton.me and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Stanozolol, with concentrations of 46.30 mg and 48.71 mg.
The testing process began on 27 September 2024, with the sample received on 22 October 2024, and analysis completed on 29 October 2024. While the results confirm the presence of Stanozolol, scrutiny of manufacturer-submitted samples remains essential to ensure consistency and reliability. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: NeoAnabolics
- Product Name: Sample 2
- Active Ingredient: Stanozolol
- Batch Number: 1
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #51313
- Testing Ordered: 27 September 2024
- Sample Received: 22 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: NeoAnabolics (Manufacturer)
- Analysis Paid For By: NeoAnabolics (Manufacturer)
Testing Results
- Measured Concentration of Stanozolol: 46.30 mg; 48.71 mg
Verification Details
Verification URL: https://janoshik.com/tests/51313_AFWC6SH46EZP
Evaluation of Manufacturer-Submitted Testing
This analysis confirms the presence of Stanozolol in the tested sample, but since the test was submitted and funded by NeoAnabolics@proton.me, careful evaluation is necessary to assess consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple samples.
Conclusion
The analysis confirms that Sample 2 contains Stanozolol in concentrations of 46.30 mg and 48.71 mg. While this batch exhibits strong quality control in terms of composition, further testing is recommended to ensure consistency and potency across multiple product batches. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding anabolic products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
